Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 13 recruiting now official registry

MDS clinical trials

Every US clinical trial registered for MDS — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.

23 US clinical trials · 13 currently recruiting

The research picture

MDS has 23 registered US clinical trials, 13 of them open to new participants right now — about 57% of the total.

13
recruiting participants now
57%
of trials open to enrollment
1
in Phase 3–4 (later-stage)
1
top sponsor: Cyclacel Pharmaceuticals

Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.

Active & Recent Trials

RECRUITING 1,000 participants

A Long Term Follow-up Study of TScan TCR-T Products

TScan Therapeutics

NCT06976736

RECRUITING Phase 2 144 participants

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

National Cancer Institute (NCI)

NCT01861106

RECRUITING Phase 1 125 participants

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

Stelexis BioSciences

NCT06533761

RECRUITING Phase 1 90 participants

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

PureTech

NCT05829226

RECRUITING Phase 1 54 participants

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Therapeutic Advances in Childhood Leukemia Consortium

NCT05476770

RECRUITING Phase 1 40 participants

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

Marker Therapeutics

NCT06552416

RECRUITING Phase 1 38 participants

BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

BlueSphere Bio

NCT06704152

RECRUITING Phase 2 37 participants

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

Franziska Wachter

NCT05796570

RECRUITING Phase 2 31 participants

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Memorial Sloan Kettering Cancer Center

NCT04644016

RECRUITING Phase 2 27 participants

BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

University of Illinois at Chicago

NCT04187105

RECRUITING Phase 1 20 participants

A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)

Treebough Therapies

NCT07006025

RECRUITING 20 participants

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

Abramson Cancer Center at Penn Medicine

NCT03680677

RECRUITING Phase 1 18 participants

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

St. Jude Children's Research Hospital

NCT06326463

ACTIVE NOT RECRUITING Phase 1 72 participants

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

Treadwell Therapeutics

NCT04730258

ACTIVE NOT RECRUITING Phase 1 61 participants

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Nkarta

NCT04623944

ACTIVE NOT RECRUITING Phase 2 42 participants

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

M.D. Anderson Cancer Center

NCT05285813

ACTIVE NOT RECRUITING Phase 2 25 participants

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

H. Lee Moffitt Cancer Center and Research Institute

NCT05177211

COMPLETED Phase 3 154 participants

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Aprea Therapeutics

NCT03745716

COMPLETED 50 participants

Ascorbic Acid Levels in MDS, AML, and CMML Patients

Van Andel Research Institute

NCT03526666

COMPLETED Phase 1 37 participants

Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells

Joanne Kurtzberg, MD

NCT00692926

COMPLETED Phase 1 21 participants

DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2

Celyad Oncology

NCT03466320

COMPLETED Phase 2 16 participants

Allogeneic Transplantation From Related Haploidentical Donors

Stanford University

NCT00185692

COMPLETED Phase 1 14 participants

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

Cyclacel Pharmaceuticals

NCT04017546

Phase Distribution

PhaseTrial count
Phase 1 12
Phase 2 7
Phase 3 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the MDS Trial Landscape

ClinicalTrials.gov lists 23 US studies indexed under MDS, and 13 of those are currently open to recruitment — roughly 57% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

The phase distribution for MDS shows 1 late-stage studies (Phase 3 and Phase 4 combined) alongside 19 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

Top sponsor activity for MDS is led by Cyclacel Pharmaceuticals with 1 indexed trial, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 23 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for MDS?

PlainTrial tracks 23 US clinical trials for MDS, of which 13 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for MDS?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Related

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →